Indicated for: benign prostatic hyperplasia
Substance: solifenacin succinate + tamsulosin (urinary antimuscarinic + alpha-1 blocker)
ATC: G04CA53 (Genito urinary system and sex hormones | Drugs used in benign prostatic hypertrophy | Alpha-adrenoreceptor antagonists)
The combination of solifenacin succinate + tamsulosin is indicated for the treatment of moderate to severe bladder storage symptoms (urinary urgency, increased urinary frequency) and bladder emptying symptoms associated with benign prostatic hyperplasia (BPH) in men who are inadequately responsive to monotherapy.
These drugs have complementary and independent mechanisms of action in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with bladder storage symptoms.
Solifenacin is a competitive and selective muscarinic receptor antagonist and does not show any relevant affinity for other receptors, enzymes or ion channels that have been tested. Solifenacin shows the highest affinity for muscarinic M3 receptors, followed by muscarinic M1 and M2 receptors.
Tamsulosin is an alpha1-adrenergic receptor (AR) antagonist. It binds selectively and competitively to post-synaptic alpha1-adrenergic receptors, especially the alpha-1A and alpha-1D subtypes, and is a potent antagonist in the lower urinary tract.